A Phase 4 interventional study of Esomeprazole + Amoxicillin + Levofloxacin + Bismuth and N-acetylcysteine (NAC) 600 mg in HELICOBACTER PYLORI INFECTIONS, sponsored by University of Thi-Qar. Completed at 1 site in Iraq. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of Thi-Qar · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Helicobacter pylori (H. pylori) is a bacterium that infects the stomach and may cause gastritis, peptic ulcer disease, and dyspeptic symptoms. Although antibiotic-based treatments are commonly used to eradicate the infection, treatment failure remains a clinical concern.
This randomized controlled trial evaluated whether adding N-acetylcysteine (NAC) or curcumin to standard treatment could improve H. pylori eradication and reduce dyspeptic symptoms.
A total of 150 adults with H. pylori infection were assigned to one of three groups: standard treatment alone, standard treatment plus NAC, or standard treatment plus curcumin. Standard treatment consisted of esomeprazole, amoxicillin, levofloxacin, and bismuth for 14 days.
The primary outcome was H. pylori eradication, assessed using a 13C-urea breath test four weeks after treatment completion. Secondary outcomes included changes in dyspeptic symptoms measured using the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) and the occurrence of adverse effects.
University of Thi-Qar is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm received standard therapy consisting of esomeprazole, amoxicillin, levofloxacin, and bismuth for 14 days, without adjunctive N-acetylcysteine or curcumin.
Drug: Esomeprazole + Amoxicillin + Levofloxacin + Bismuth
Participants in this arm received standard therapy consisting of esomeprazole, amoxicillin, levofloxacin, and bismuth for 14 days, with adjunctive N-acetylcysteine.
Drug: Esomeprazole + Amoxicillin + Levofloxacin + Bismuth · Drug: N-acetylcysteine (NAC) 600 mg
Participants in this arm received standard therapy consisting of esomeprazole, amoxicillin, levofloxacin, and bismuth for 14 days, with adjunctive curcumin.
Drug: Esomeprazole + Amoxicillin + Levofloxacin + Bismuth · Drug: Curcumin (Turmeric)
The standard treatment regimen consisted of esomeprazole, amoxicillin, levofloxacin, and bismuth administered orally for 14 days. This regimen was used in all three study arms, either alone or in combination with N-acetylcysteine or curcumin.
N-Acetylcysteine was administered orally as an adjunct to the standard treatment regimen for Helicobacter pylori eradication.
Curcumin was administered orally as an adjunct to the standard treatment regimen for Helicobacter pylori eradication.
Helicobacter pylori Eradication Rate
The proportion of participants achieving successful Helicobacter pylori eradication, defined as a negative 13C-urea breath test (UBT) performed four weeks after completion of the 14-day treatment regimen. Eradication rates were compared among the three treatment groups.
Time frame: 4 weeks after completion of treatment
Change in Dyspeptic Symptoms (SF-LDQ Score)
Change in dyspeptic symptoms was assessed using the Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ). The questionnaire evaluates indigestion, heartburn, acid regurgitation, and nausea. Total scores range from 0 to 32, with higher scores indicating greater symptom burden. Change was calculated as the post-treatment score minus the baseline score; negative values indicate symptom improvement.
Time frame: Baseline and approximately 2 months after baseline
Incidence of Treatment-Related Adverse Effects
The proportion of participants reporting at least one adverse effect during the 14-day treatment period was assessed in each study group. Adverse effects were documented through patient follow-up and compared among the three treatment groups.
Time frame: During the 14-day treatment period
Plan to share: No — Individual participant data will not be publicly shared due to patient confidentiality and privacy considerations. Only aggregated and anonymized study results will be reported in scientific publications.
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Sep 2026, 8 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetylcysteine · Curcumin